Literature DB >> 3429389

Activity of macrolides against organisms responsible for respiratory infection with emphasis on Mycoplasma and Legionella.

K Hara1, N Suyama, K Yamaguchi, S Kohno, A Saito.   

Abstract

The activity of roxithromycin against Legionella pneumophila in vitro was approximately the same as that of rokitamycin and superior to those of erythromycin and josamycin. In experimental pneumonia due to L. pneumophila none of the animals in the roxithromycin and rifampicin groups died by day 10 of the infection. The MIC ranges of roxithromycin, erythromycin and rokitamycin for Mycoplasma pneumoniae were 0.008-0.063, 0.004-0.008 and 0.016-greater than 125, respectively. In experimental pneumonia caused by M. pneumoniae, roxithromycin showed good activity similar to that of erythromycin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3429389     DOI: 10.1093/jac/20.suppl_b.75

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 4.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

Review 5.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

6.  Role of long-term azithromycin therapy for severe bronchial asthma.

Authors:  Mohamed S Al-Hajjaj; Mohamed S Al Moamary
Journal:  Ann Thorac Med       Date:  2020-04-03       Impact factor: 2.219

7.  Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials.

Authors:  Gerald Chi; Sahar Memar Montazerin; Jane J Lee; Syed Hassan A Kazmi; Fahimehalsadat Shojaei; Clara Fitzgerald; C Michael Gibson
Journal:  J Med Virol       Date:  2021-08-17       Impact factor: 20.693

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.